Patent application number | Description | Published |
20090005312 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS - Novel GLP-1 agonists which are protracted by coupling to a protraction protein. | 01-01-2009 |
20090088388 | Peptides for Use In Treating Obesity - Novel cyclic and linear peptides of the formula R | 04-02-2009 |
20090111730 | Polypeptide protracting tags - Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere. | 04-30-2009 |
20090156478 | Acylated GLP-1 Compounds - Protracted GLP-1 compounds and therapeutic uses thereof. | 06-18-2009 |
20090176700 | Derivatives Of GLP-1 Analogs - The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant. | 07-09-2009 |
20100292133 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 11-18-2010 |
20100305032 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 12-02-2010 |
20110053839 | GLP-1 Derivatives II - The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue. | 03-03-2011 |
20110306551 | Modification of Factor VIII - A Factor VIII derivative of formula (I): wherein: B represents C | 12-15-2011 |
20120088716 | Polypeptide Protracting Tags - Method for increasing half-life of compounds in plasma and novel derivatives of such compounds. | 04-12-2012 |
20120295847 | Acylated GLP-1 Compounds - Protracted GLP-1 compounds and therapeutic uses thereof. | 11-22-2012 |
20130040884 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG - Novel polypeptide derivatives having protracted profile of action. | 02-14-2013 |
20130053315 | NOVEL GLP-1 DERIVATIVES - Novel polypeptide derivatives having protracted profile of action. | 02-28-2013 |
20130244931 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 09-19-2013 |
Patent application number | Description | Published |
20120283170 | Acylated Exendin-4 Compounds - This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such. | 11-08-2012 |
20120289453 | NOVEL GLP-1 COMPOUNDS - Novel GLP-1 compounds and their therapeutic use. | 11-15-2012 |
20130143815 | GROWTH HORMONE CONJUGATES - The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant. | 06-06-2013 |
20140296131 | Truncated GLP-1 Derivatives and Their Therapeutical Use - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 10-02-2014 |